Next Article in Journal
Cisplatin Reduces the Frequencies of Radiotherapy-Induced Micronuclei in Peripheral Blood Lymphocytes of Patients with Gynaecological Cancer: Possible Implications for the Risk of Second Malignant Neoplasms
Next Article in Special Issue
Modulation of Immune Components on Stem Cell and Dormancy in Cancer
Previous Article in Journal
Biochemistry, Pathophysiology, and Regulation of Linear Ubiquitination: Intricate Regulation by Coordinated Functions of the Associated Ligase and Deubiquitinase
Previous Article in Special Issue
Co-Expression of CD34, CD90, OV-6 and Cell-Surface Vimentin Defines Cancer Stem Cells of Hepatoblastoma, Which Are Affected by Hsp90 Inhibitor 17-AAG

Redox Control of the Dormant Cancer Cell Life Cycle

by 1,2,†, 3,†, 2,†, 4, 1,* and 1,2,*
The Affiliated Hospital of Medical School of Ningbo University, Ningbo 315020, China
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital and West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
Clinical Medical College, Hubei University of Science and Technology, Xianning 437000, China
Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia
Authors to whom correspondence should be addressed.
These authors contributed equally to this paper.
Academic Editor: Ming Luo
Cells 2021, 10(10), 2707;
Received: 19 August 2021 / Revised: 11 September 2021 / Accepted: 28 September 2021 / Published: 9 October 2021
(This article belongs to the Special Issue Targeting Cancer Stem Cell)
Following efficient tumor therapy, some cancer cells may survive through a dormancy process, contributing to tumor recurrence and worse outcomes. Dormancy is considered a process where most cancer cells in a tumor cell population are quiescent with no, or only slow, proliferation. Recent advances indicate that redox mechanisms control the dormant cancer cell life cycle, including dormancy entrance, long-term dormancy, and metastatic relapse. This regulatory network is orchestrated mainly through redox modification on key regulators or global change of reactive oxygen species (ROS) levels in dormant cancer cells. Encouragingly, several strategies targeting redox signaling, including sleeping, awaking, or killing dormant cancer cells are currently under early clinical evaluation. However, the molecular mechanisms underlying redox control of the dormant cancer cell cycle are poorly understood and need further exploration. In this review, we discuss the underlying molecular basis of redox signaling in the cell life cycle of dormant cancer and the potential redox-based targeting strategies for eliminating dormant cancer cells. View Full-Text
Keywords: cancer dormancy; redox signaling; cancer therapy; ROS cancer dormancy; redox signaling; cancer therapy; ROS
Show Figures

Figure 1

MDPI and ACS Style

Li, B.; Huang, Y.; Ming, H.; Nice, E.C.; Xuan, R.; Huang, C. Redox Control of the Dormant Cancer Cell Life Cycle. Cells 2021, 10, 2707.

AMA Style

Li B, Huang Y, Ming H, Nice EC, Xuan R, Huang C. Redox Control of the Dormant Cancer Cell Life Cycle. Cells. 2021; 10(10):2707.

Chicago/Turabian Style

Li, Bowen, Yichun Huang, Hui Ming, Edouard C. Nice, Rongrong Xuan, and Canhua Huang. 2021. "Redox Control of the Dormant Cancer Cell Life Cycle" Cells 10, no. 10: 2707.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop